ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Novel therapeutics in autism spectrum disorder.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in neuropsychiatry: From objective diagnostics to mechanism-based therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition with limited treatment options that address its full complexity. This review critically evaluates novel therapeutics across five key domains: behavioral and psychosocial interventions, psychopharmacology, digital and AI-driven tools, neuromodulation, and genetic therapies. The broad heterogeneity of ASD complicates clinical research, often obscuring treatment effects and limiting generalizability. Challenges across domains include identifying reliable biomarkers, defining meaningful outcomes, and ensuring equitable access to evidence-based care and research participation. Behavioral and psychosocial therapies, considered first line interventions, are shifting toward naturalistic, developmentally informed, and neurodiversity-affirming models that reflect individual needs across the spectrum and across the lifespan. There continues to be no medications that are currently FDA approved for core autism symptoms, though ongoing pharmacologic research increasingly emphasizes biologically informed, stratified approaches to develop biomarkers that identify subsets of individuals who may benefit from a specific treatment. Digital and AI-driven tools promise greater personalization and expanded access but require safeguards, validation, and attention to equity. Neuromodulation techniques, including Transcranial Magnetic Stimulation (TMS) and Transcranial Direct Current Stimulation (tDCS), remain experimental yet highlight the importance of personalized protocols and ethical oversight. Genetics has seen advancements in gene-targeted therapies for syndromic forms of ASD marking a pivotal move toward precision medicine in autism, though ongoing challenges regarding safety, efficacy, and equitable access persist. This review informs clinicians, researchers, individuals with lived experiences and other important stakeholders by appraising current evidence, identifying limitations, and outlining future directions to advance rigorous, inclusive, and collaborative autism therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.